Stem cell transplantation

High-dose melphalan treatment significantly increases mutational burden at relapse in multiple myeloma

Samur MK, Roncador M, Aktas Samur A, …, Szalat R, …, Munshi NC

Blood141(14):1724-1736DOI: High-dose melphalan treatment significantly increases mutational burden at relapse in multiple myelomaPubMed: High-dose melphalan treatment significantly increases mutational burden at relapse in multiple myeloma

Predictors of hematologic response and survival with stem cell transplantation in AL amyloidosis: A 25‐year longitudinal study

Gustine JN, Staron A, Szalat RE, …, Sanchorawala V

American Journal of Hematology97(9):1189-1199DOI: Predictors of hematologic response and survival with stem cell transplantation in AL amyloidosis: A 25‐year longitudinal studyPubMed: Predictors of hematologic response and survival with stem cell transplantation in AL amyloidosis: A 25‐year longitudinal study

Genome-Wide Somatic Alterations in Multiple Myeloma Reveal a Superior Outcome Group

Samur MK, Aktas Samur A, Fulciniti M, Szalat R, …, Munshi NC

Journal of Clinical Oncology38(27):3107-3118DOI: Genome-Wide Somatic Alterations in Multiple Myeloma Reveal a Superior Outcome GroupPubMed: Genome-Wide Somatic Alterations in Multiple Myeloma Reveal a Superior Outcome Group

Organ responses after highdose melphalan and stemcell transplantation in AL amyloidosis

Szalat R, Sarosiek S, Havasi A, Brauneis D, Sloan JM, Sanchorawala V

Leukemia35(3):916-919DOI: Organ responses after highdose melphalan and stemcell transplantation in AL amyloidosisPubMed: Organ responses after highdose melphalan and stemcell transplantation in AL amyloidosis

Consolidation with VTd significantly improves the complete remission rate and time to progression following VTd induction and single autologous stem cell transplantation in multiple myeloma

Leleu X, Fouquet G, Hebraud B, …, Szalat R, …, (IFM) OBOIFDM

Leukemia27(11):2242-2244DOI: Consolidation with VTd significantly improves the complete remission rate and time to progression following VTd induction and single autologous stem cell transplantation in multiple myelomaPubMed: Consolidation with VTd significantly improves the complete remission rate and time to progression following VTd induction and single autologous stem cell transplantation in multiple myeloma

Real-world one-year comparative outcomes of quadruplet and triplet induction regimens in older, transplant-ineligible multiple myeloma patients.

Cetin O, Teker G, Szalat RE

Journal of Clinical Oncology44(16_suppl):7567-7567DOI: Real-world one-year comparative outcomes of quadruplet and triplet induction regimens in older, transplant-ineligible multiple myeloma patients.

High-Dose Melphalan Significantly Increases Mutational Burden in Multiple Myeloma Cells at Relapse: Results from a Randomized Study in Multiple Myeloma

Samur MK, Roncador M, Aktas-Samur A, …, Szalat R, …, Munshi NC

Blood136(Supplement 1):4-5DOI: High-Dose Melphalan Significantly Increases Mutational Burden in Multiple Myeloma Cells at Relapse: Results from a Randomized Study in Multiple Myeloma

Consolidation with VTd Improves the CR Rate Following VTd Induction and Single Autotransplantation in Multiple Myeloma: P-137

XAVIER L, LELEU X, FOUQUET G, HEBRAUD B, ROUSSEL M, et al.

Clinical Lymphoma, Myeloma & Leukemia13:s108-s109

Consolidation with Vtd Significantly Improves the Complete Remission (CR) Rate Following Vtd Induction and Single Autologous Stem Cell Transplantation (auto) in Multiple Myeloma (MM).

Leleu X, Hebraud B, Fouquet G, …, Szalat R, …, Moreau P

Blood120(21):3096-3096DOI: Consolidation with Vtd Significantly Improves the Complete Remission (CR) Rate Following Vtd Induction and Single Autologous Stem Cell Transplantation (auto) in Multiple Myeloma (MM).

Impact of Tandem Autologous/Non Myeloablative Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Multiple Myeloma Relapsing After a First High Dose Therapy in the Era of Novels Anti-Myeloma Agents

Harel S, Bernard S, Chevret S, …, Szalat R, …, Socie G

Blood120(21):2035-2035DOI: Impact of Tandem Autologous/Non Myeloablative Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Multiple Myeloma Relapsing After a First High Dose Therapy in the Era of Novels Anti-Myeloma Agents

Total Body Irradiation (TBI) or Busulfan (Bu) Plus High Dose Melphalan After Bortezomib (Bz) Containing Regimen As Front Line Treatment of High Risk Multiple Myeloma (MM) Patients with 17p Deletion and/or t(4;14) Translocation

Arnulf B, Szalat R, Karlin L, Harel S, Asli B, Malphettes M, Soulier J, Fermand JP

Blood118(21):4501-4501DOI: Total Body Irradiation (TBI) or Busulfan (Bu) Plus High Dose Melphalan After Bortezomib (Bz) Containing Regimen As Front Line Treatment of High Risk Multiple Myeloma (MM) Patients with 17p Deletion and/or t(4;14) Translocation